Wei Wu, Ph.D. is currently the Healthcare Investment Director of BOE Ventures, the corporate venture arm of BOE Technology Group. She is also the Co-Chair of Biotech/Genomics investment committee of Life Science Angels, the No. 1 angel investment group in US ranked by CB Insights. Her advisory roles include advising Stanford SPARK translational research program and Berkeley SkyDeck – the official accelerator affiliated with UC Berkeley. Prior to being a venture capitalist, she was a R&D project lead at NuGEN Technologies that was acquired by TECAN Group AG. Her investment areas cover genomics, research tool, diagnostics, health-tech, and pharmaceuticals including various new modalities (gene therapy/cell therapy/bioelectronic medicine).
Wei received B.S. in Biological Sciences from Peking University, and Ph.D. in Biological Chemistry/Neuroscience from UCLA. She completed her postdoctoral training in Regenerative Medicine/Epigenomics at Stanford University School of Medicine. She was trained by two National Academy of Sciences members and published in journals including Cell, Nature, Neuron, and Nature Reviews Genetics. She was a bronze medalist of the 12th International Biology Olympiad.